<DOC>
	<DOCNO>NCT02307643</DOCNO>
	<brief_summary>The purpose study evaluate safety/tolerability explore efficacy MT-1303 subject systemic lupus erythematosus</brief_summary>
	<brief_title>Exploratory Study MT-1303 Systemic Lupus Erythematosus Patients</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE base American College Rheumatology ( ACR ) criterion Presence least one follow item : positive anti dsDNA antibody , low complement level , . Stable dos corticosteroid Severe active lupus nephritis , neuropsychiatric SLE</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Systemic lupus erythematosus</keyword>
</DOC>